For patients with PD-L1 expression that is negative or between 1% and 49% (determined in tumor cells), non-squamous cell carcinoma, and PS of 0–1, the recommended treatment is pembrolizumab in combination with carboplatin and pemetrexed. This evidence concerns the gene CD274 and neoplasm.